Select a Region North America

最新观点

Insights From Our Experts

Articles

Bridging “Share of Voice” with “Share of Influence” for Lasting Impact

In today’s complex healthcare environment, manufacturers must navigate an evolving stakeholder landscape to guarantee patient access and successful product launches. This article explores how deploying a strategic approach that establishes a “share of influence” across the…

Celebrating Excellence: Two EVERSANA Leaders Named to PM360 Elite 100 List

We’re excited to share that two EVERSANA leaders have been recognized in the prestigious 2024 PM360 ELITE 100 List. PM360 ELITE celebrates individuals who exemplify excellence and innovation in the healthcare industry. Highlighted among this year’s…

IDNs: Driving Change in Drug Access and Utilization

As of May 2024, a striking 77.6% of physicians in the United States are employed by hospitals, health systems and corporate entities – a significant surge from less than 50% a mere decade ago. This trend…

Real-World Insights: Effectiveness and Safety of Crizotinib in ROS1-Rearranged NSCLC

Lung cancer is one of the most incident malignancies and the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases and, with the emergence of genomic techniques,…

Demystifying the New Prescription Drug Use-Related Software Framework

Authors: Martin Culjat, PhD , Kory Dillman​ and Scott Kellogg The Food and Drug Administration (FDA) unveiled its draft guidance on Regulatory Considerations for Prescription Drug Use-Related Software (PDURS) in September 2023. The document shed light on how the…

Price Right or Pay Later

Dive into the intricate world of pharmaceutical pricing with “Price Right or Pay Later” by Christopher Nüesch, Chad McAuliffe, and Andrew Therrien. In this groundbreaking paper, EVERSANA exposes the critical yet often overlooked nuances of pricing…

Leveraging Generative AI in Brand Planning: Insights from Second Annual Pharmaceutical Brand Planning Survey

Discover the cutting-edge insights from EVERSANA’s second annual Pharmaceutical Brand Planning Survey. Dive into the burgeoning trend of integrating generative AI into brand planning within the life sciences sector. This comprehensive report, based on responses from…

Maximizing Sales Impact in a Hybrid World

In an evolving pharmaceutical landscape, traditional sales methods are giving way to a new hybrid approach. “Maximizing Sales Impact in a Hybrid World” delves into this transformative shift, exploring how data-driven strategies blend personal and non-personal…

Equip FRMs with the Right Tools to Unlock Patient Access

In the modern healthcare landscape, multiple daunting challenges muddy pharmaceutical manufacturers’ ability to ensure patients have timely and uncomplicated access to high-quality care and life-altering medications. A plethora of obstacles can impede the processes of finding…

Unveiling Challenges: Analyzing Stakeholder Feedback on the EU Joint Clinical Assessment Implementation Act and Its Impact on the Latest Draft

On March 5, 2024, the draft Implementation Act (IA) for Joint Clinical Assessment (JCA) for medicinal products was released for public comments. The intent of the draft IA was to provide more granular details on the…